Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data
A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs
You may also be interested in...
Synthetic Biologics emerged from meetings with US FDA without its breakthrough designation, but with hope that agency will allow decoupling of safety and efficacy endpoints in planned Phase III trial for prevention of C. difficile infection.
Despite the agency’s decision to limit discussion about missing data to the ATLAS pivotal trial of rivaroxaban, Cardio-Renal advisory committee members suggested reforms that sponsors should consider to prevent the kinds of problems seen in ATLAS.
The new indication for Lilly's SNRI would expose a much larger patient population to the risk of liver injury. The FDA reviewer and his supervisors disagree about how to handle the concern.